What is Polaryx Therapeutics, Inc. 's business segments — stock-based comp?

Polaryx Therapeutics, Inc. (PLYX) reported business segments — stock-based comp of $467.00K in Q1 2026.

What does business segments — stock-based comp mean?

The non-cash cost of stock-based incentives provided to staff working on lysosomal storage disorder projects.

Polaryx Therapeutics, Inc. Business Segments — Stock-Based Comp decreased by 89.5% to $467.00K in Q1 2026 compared to the prior quarter.

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

Higher levels indicate significant investment in talent retention, while lower levels may reflect changes in compensation strategy or headcount.

This metric represents the non-cash expense recognized for equity-based awards granted to employees and consultants work...

Standard practice across the biotech industry to report equity compensation as a component of total operating expenses.

Metric ID: plyx_segment_lysosomal_storage_disorders_share_based_compensation

2 periods

Range$467.00K – $4.45M

Avg YoY Growth-89.5%

Median YoY Growth-89.5%

What is Polaryx Therapeutics, Inc. 's business segments — stock-based comp?: Polaryx Therapeutics, Inc. (PLYX) reported business segments — stock-based comp of $467.00K in Q1 2026.
What does business segments — stock-based comp mean?: The non-cash cost of stock-based incentives provided to staff working on lysosomal storage disorder projects.